ReviewJAC-antimicrobial resistance2025
The global epidemiology of carbapenem-resistant
Review in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Article
- Distribution of Non-Fermenting Gram-Negative Bacilli and Carbapenem Resistance Profiles in Intensive Care Units of a Foundation University Hospital: A 2023-2025 Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Prevalence and antimicrobial resistance trends of ESKAPEE pathogens in clinical isolates from Hyderabad, Pakistan: a cross-sectional study.IJID regions · 2026Article
- Molecular and Structural Insights ofAntibiotics (Basel, Switzerland) · 2026Article
- Whole-Genome Analysis Reveals Antimicrobial Resistance and Population Structure of Environmental and VeterinaryInternational journal of molecular sciences · 2026Article
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- Genomic epidemiology of carbapenem resistance inJAC-antimicrobial resistance · 2026Article
- Site-specific and time-varying Acinetobacter colonization and risk of invasive infection in critically ill patients.Infection · 2026Article
- Genotypic and Phenotypic Resistance Profiles of InvasiveMicroorganisms · 2026Article
- Phytochemical Characterisation and Skin-Relevant In Vitro Biological Activity of Leaf Extracts from SelectedMolecules (Basel, Switzerland) · 2026Article
- Repurposing bleomycin against Acinetobacter baumannii HisG: computational, biophysical, and antibacterial evidence.Journal of computer-aided molecular design · 2026Article
- Comprehensive identification of sequence types belonging toMicrobial genomics · 2026Article
- Investigation of Biofilm Formation and Antimicrobial Resistance in Bacteria Isolated from Hospital Medical Devices.Microorganisms · 2026Article
- Computational identification of marine-derived therapeutic leads targeting the acyl-homoserine-lactone synthase (AHL) in drug-resistant Acinetobacter baumannii (Strain AYE).Molecular diversity · 2026Article
- The Rise in Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Clinical Severity and Organ Dysfunction as Drivers of Mortality in Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Linalool exhibits potent antibacterial and anti-biofilm activity against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Prevalence, antimicrobial resistance, and associated factors of critical superbugs Klebsiella pneumoniae and Acinetobacter species among hospitalized patients in Northwest Ethiopia.BMC microbiology · 2026Article
- Carbapenem-resistantJAC-antimicrobial resistance · 2026Article
- Redefining Antimicrobial Resistance inInternational journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.